Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 1502 to 1551 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1502\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"CIRHIN; TESTIS EXPRESSED GENE 292; CIRRHOSIS, AUTOSOMAL RECESSIVE 1A. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.588096\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.42296\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242717998\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CIRH1A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1503\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ZUOTIN RELATED FACTOR-1 (M-PHASE PHOSPHOPROTEIN 11). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0271819\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.112006\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242682535\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ZRF1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1504\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GUANINE NUCLEOTIDE-BINDING PROTEIN BETA SUBUNIT-LIKE PROTEIN 12.3 (P205) (RECEPTOR OF ACTIVATED PROTEIN KINASE C 1) (RACK1) (RECEPTOR FOR ACTIVATED C KINASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.112103\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.461933\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24268238\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1505\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PBK1 PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.485772\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.00168\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242682147\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RSL1D1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1506\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
WD-REPEAT PROTEIN BING4. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.562114\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.31688\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242616795\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
WDR46\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1507\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.511781\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
2.10953\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.242604277\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
NOC4L\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1508\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROBABLE RIBOSOME BIOGENESIS PROTEIN NEP1 (C2F PROTEIN). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
EMG1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1509\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EXOCYST COMPLEX COMPONENT SEC6. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0383868\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.158229\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24260281\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EXOC3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1510\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.11516\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.474687\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242601967\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C19orf50\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1511\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.0256005\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.105559\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242523139\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NGDN\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1512\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
APOPTOSIS ANTAGONIZING TRANSCRIPTION FACTOR. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.46077\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.89991\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242522014\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
AATF\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1513\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0884483\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.36491\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242383875\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ATPBD4\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1514\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.332106\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.37021\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242375986\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
WDSOF1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1515\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (CYTOSOLIC INHIBITOR OF NRF2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0838767\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.346067\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242371275\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KEAP1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1516\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DNA REPLICATION LICENSING FACTOR MCM3 (DNA POLYMERASE ALPHA HOLOENZYME-ASSOCIATED PROTEIN P1) (RLF BETA SUBUNIT) (P102 PROTEIN) (P1-MCM3). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0279589\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.115356\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242370575\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MCM3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1517\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GLIA MATURATION FACTOR GAMMA (GMF-GAMMA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0675774\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.278856\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242337981\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GMFG\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1518\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SUPPRESSOR OF CYTOKINE SIGNALING 1 (SOCS-1) (JAK-BINDING PROTEIN) (JAB) (STAT INDUCED STAT INHIBITOR 1) (SSI-1) (TEC-INTERACTING PROTEIN 3) (TIP-3). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0338352\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.13962\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.242337774\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
SOCS1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1519\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FK506-BINDING PROTEIN 1A (EC 5.2.1.8) (PEPTIDYL-PROLYL CIS-TRANS ISOMERASE) (PPIASE) (ROTAMASE) (12 KDA FKBP) (FKBP-12) (IMMUNOPHILIN FKBP12). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
FKBP1A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1520\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.161284\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.665535\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242337368\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PAN3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1521\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ASC-1 COMPLEX SUBUNIT P100. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0336999\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.139062\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242337231\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ASCC2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1522\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.101184\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.417534\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242337151\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RBM22\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1523\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUCLEOLAR PROTEIN NOP56 (NUCLEOLAR PROTEIN 5A). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.66215\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.73239\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242333635\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NOL5A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1524\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE M1 CHAIN (EC 1.17.4.1) (RIBONUCLEOTIDE REDUCTASE LARGE CHAIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.123369\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.509096\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242329541\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RRM1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1525\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KINESIN-LIKE PROTEIN KIF3B (MICROTUBULE PLUS END-DIRECTED KINESIN MOTOR 3B) (HH0048). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.105382\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.43488\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242324319\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KIF3B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1526\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DOWN-REGULATED IN METASTASIS. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.17672\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4.8561\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242317909\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UTP20\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1527\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 3; RHOGEF PROTEIN; 59.8 KDA PROTEIN; EXCHANGE FACTOR FOUND IN PLATELETS AND LEUKEMIC AND NEURONAL TISSUES, XPLN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0223435\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0922076\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242317336\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ARHGEF3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1528\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NEUROEPITHELIAL CELL TRANSFORMING GENE 1; GUANINE NUCLEOTIDE REGULATORY PROTEIN (ONCOGENE); RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) 8. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0256013\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.105652\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24231723\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NET1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1529\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KINESIN-LIKE PROTEIN KIF3C. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0849863\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.350755\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242295334\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KIF3C\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1530\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EUKARYOTIC TRANSLATION INITIATION FACTOR 6 (EIF-6) (B4 INTEGRIN INTERACTOR) (CAB) (P27(BBP)) (B(2)GCN HOMOLOG). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.850503\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.51033\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242285768\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EIF6\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1531\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ATP-DEPENDENT RNA HELICASE ROK1; ATP-DEPENDENT RNA HELICASE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0764864\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.315775\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242218035\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DDX52\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1532\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NIN ONE BINDING PROTEIN; ADENOCARCINOMA ANTIGEN RECOGNIZED BY T LYMPHOCYTES 4. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0805704\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.332683\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.2421837\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NOB1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1533\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NADH-UBIQUINONE OXIDOREDUCTASE PDSW SUBUNIT (EC 1.6.5.3) (EC 1.6.99.3) (COMPLEX I-PDSW) (CI-PDSW). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.322293\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.3313\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242088936\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NDUFB10\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1534\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
IRON-RESPONSIVE ELEMENT BINDING PROTEIN 1 (IRE-BP 1) (IRON REGULATORY PROTEIN 1) (IRP1) (FERRITIN REPRESSOR PROTEIN) (ACONITATE HYDRATASE) (EC 4.2.1.3) (CITRATE HYDRO-LYASE) (ACONITASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.195279\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.806892\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242013801\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ACO1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1535\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UBIQUITIN-CONJUGATING ENZYME E2 N (EC 6.3.2.19) (UBIQUITIN-PROTEIN LIGASE N) (UBIQUITIN CARRIER PROTEIN N) (UBC13) (BENDLESS-LIKE UBIQUITIN CONJUGATING ENZYME). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.132301\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.546679\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.242008564\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UBE2N\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1536\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"5-FORMYLTETRAHYDROFOLATE CYCLO-LIGASE (EC 6.3.3.2) (5,10-METHENYL- TETRAHYDROFOLATE SYNTHETASE) (METHENYL-THF SYNTHETASE) (MTHFS). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0691225\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.285651\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241982349\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MTHFS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1537\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"INHIBITOR OF GROWTH FAMILY, MEMBER 1; INHIBITOR OF GROWTH 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.111297\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.459981\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241959994\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ING1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1538\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSLATION INITIATION FACTOR EIF-2B DELTA SUBUNIT (EIF-2B GDP-GTP EXCHANGE FACTOR). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.287772\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.18956\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241914658\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EIF2B4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1539\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HISTONE H3.3 (H3.A) (H3.B) (H3.3Q). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.21933\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.906671\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241906932\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
1540\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DJ1099D15.1 (PUTATIVE DNAJ PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0214576\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0887019\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241906881\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1541\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"DNA-DIRECTED RNA POLYMERASES I, II, AND III 17.1 KDA POLYPEPTIDE (EC 2.7.7.6) (RPB17) (RPB8) (RPABC3). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.345751\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.42971\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241832959\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
POLR2H\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1542\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUCLEAR FACTOR NF-KAPPA-B P100/P49 SUBUNITS (H2TF1) (ONCOGENE LYT-10) (LYT10) [CONTAINS: NUCLEAR FACTOR NF-KAPPA-B P52 SUBUNIT]. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.415216\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.71705\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.2418194\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NFKB2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1543\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NF-KAPPAB INHIBITOR BETA (NF-KAPPA-BIB) (I-KAPPA-B-BETA) (IKAPPABBETA) (IKB-BETA) (IKB-B) (THYROID RECEPTOR INTERACTING PROTEIN 9) (TR- INTERACTING PROTEIN 9). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.414708\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.71495\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241819295\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NFKBIB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1544\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUCLEAR FACTOR NF-KAPPA-B P105 SUBUNIT (DNA-BINDING FACTOR KBF1) (EBP- 1) [CONTAINS: NUCLEAR FACTOR NF-KAPPA-B P50 SUBUNIT]. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.415555\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.71846\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241818256\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NFKB1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1545\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
B-CELL LYMPHOMA 3-ENCODED PROTEIN (BCL-3 PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.424367\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.75491\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241816959\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BCL3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1546\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"INHIBITOR OF GROWTH FAMILY, MEMBER 1-LIKE; INHIBITOR OF GROWTH 1-LIKE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.132686\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.548709\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241814878\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ING2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1547\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NF-KAPPAB INHIBITOR EPSILON (NF-KAPPA-BIE) (I-KAPPA-B-EPSILON) (IKAPPABEPSILON) (IKB-EPSILON) (IKBE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.56383\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.33188\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24179203\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NFKBIE\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1548\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VACUOLAR ATP SYNTHASE SUBUNIT D (EC 3.6.3.14) (V-ATPASE D SUBUNIT) (VACUOLAR PROTON PUMP D SUBUNIT) (V-ATPASE AC39 SUBUNIT) (V-ATPASE 40 KDA ACCESSORY PROTEIN) (P39) (32 KDA ACCESSORY PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.584458\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.4172\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241791329\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ATP6V0D1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1549\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ADP-RIBOSYLATION FACTOR-LIKE PROTEIN 4. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0296714\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.122715\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241791142\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ARL4A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1550\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ADP-RIBOSYLATION FACTOR-LIKE PROTEIN 7 (ADP-RIBOSYLATION FACTOR-LIKE PROTEIN LAK). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0364961\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.150941\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241790501\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1551\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.129986\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.53787\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241668061\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PDRG1\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/